Pharma Stocks
-
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company”…
Read More » -
Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation After European Approval for Key Biosimilars
Teva Pharmaceutical Industries (NYSE:TEVA) has received European Commission approval for its biosimilars PONLIMSI and DEGEVMA. This development strengthens its position…
Read More » -
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On Wednesday – Arrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL)
U.S. stocks were higher, with the Dow Jones gaining over 300 points on Wednesday. Shares of Urban Outfitters Inc (NASDAQ:URBN)…
Read More » -
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Adial Pharmaceuticals, Inc GLEN ALLEN, Va., Nov. 26, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the…
Read More » -
SMS Pharmaceuticals shares soar 17% after USFDA approves reformulated Ranitidine tablets
SMS Pharmaceuticals share price surged almost 17% today following the news that the US Food and Drug Administration (USFDA) has…
Read More » -
Bal Pharma Stock Falls to 52-Week Low of Rs.75 Amidst Prolonged Downtrend
Recent Price Movement and Market Context On 24 Nov 2025, Bal Pharma’s share price touched an intraday low of Rs.75,…
Read More » -
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects
Milestone Pharmaceuticals (NASDAQ:MIST) is one of the Canadian penny stocks to buy right now. On November 13, analysts at Jefferies…
Read More » -
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?
With a market cap of $1 trillion, Eli Lilly and Company (LLY) is one of the world’s leading pharmaceutical innovators, known for…
Read More » -
Sudarshan Pharma Industries Faces Intense Selling Pressure Amid Consecutive Losses
Market Performance Overview On 25 Nov 2025, Sudarshan Pharma Industries recorded a day’s loss of 4.96%, markedly underperforming the Sensex,…
Read More » -
At 21x P/E, is Lupin an undervalued pharma giant poised for the next growth cycle? | Smart Stocks News
After a two-year cyclical rally from April 2023 to December 2024, Indian pharma stocks plateaued through 2025. Lupin and Zydus…
Read More »